Biotech Stocks Summit Therapeutics and Fractyl Health See Substantial Increase in Search Activity
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:Summit Therapeutics, 130.37% surge in interestFractyl Health, 66.4% surge in interestPipeline and key clinical candidates for these companies:Summit Therapeuticsis a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.Fractyl Healthis a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl's goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease.Recent news on these stocks:April 7Stifel initiated coverage of Summit Therapeutics with a Buy rating and $45 price target. The firm believes the company's ivonescimab, a "first-in-class" PD-1xVEGF bispecific antibody, is positioned to lead in what could be a $200B drug class. The growing strategic capital committed to "fast-followers" suggests scarcity value in Summit's competitive positioning, the analyst tells investors in a research note. Stifel thinks the "de-risking" of Summit's first-line lung cancer trials "could trigger an overdue re-rating" of the shares.Hear more from InvestingChannel by signing up for.About "Biotech Alert"The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel's online financial news media ecosystem.This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Trade with 70% Backtested Accuracy
Analyst Views on SMMT
About SMMT
About the author
Aehr Test Systems and MongoDB Show Active Options Trading
- Aehr Options Volume: Aehr Test Systems has seen an options trading volume of 23,837 contracts today, equating to approximately 2.4 million shares, which represents 69.3% of its average daily trading volume of 3.4 million shares over the past month.
- High Contract Analysis: Notably, the $90 strike call option expiring on April 17, 2026, has traded 1,933 contracts today, representing about 193,300 underlying shares, indicating market expectations for future price increases.
- MongoDB Options Activity: MongoDB Inc recorded an options trading volume of 10,127 contracts, representing approximately 1.0 million shares or 65.6% of its average daily trading volume of 1.5 million shares over the past month, highlighting investor interest in its future performance.
- Put Option Trading: The $230 strike put option expiring on April 17, 2026, has seen 714 contracts traded today, representing about 71,400 underlying shares, reflecting market concerns regarding potential downside risks for MongoDB.
Stifel Begins Coverage of Summit Therapeutics Inc with a Buy Rating and Sets Price Target at $45
Company Overview: Summit Therapeutics is focused on developing innovative therapies, particularly in the field of rare diseases and infectious diseases.
Investment Rating: The company has received a "Buy" rating from analysts, indicating positive expectations for its stock performance.
Price Target: Analysts have set a price target of $45 for Summit Therapeutics, suggesting significant potential for growth.
Market Position: The company is positioned to capitalize on its therapeutic developments, which may enhance its market presence and investor interest.
Citi Identifies Stocks with Upside Amid U.S.-Iran Conflict
- Market Turmoil Impact: The ongoing U.S.-Iran conflict has caused concern among investors, leading to a nearly 8% drop in the S&P 500 in March, marking its worst monthly performance since 2022.
- Citi Analyst Strategy: Citi analyst Richard Schlatter sought stocks that could sidestep recent volatility by overlaying crowding composites tracked by Citi, identifying stocks with positive catalysts that are not relatively crowded, aiming for a favorable reaction to fundamental tailwinds.
- Delta Air Lines Outlook: Delta Air Lines' stock has only dropped 3.8% this month, despite a nearly 9% decline in 2026, with Wall Street expecting a rebound; the average analyst price target from LSEG suggests a potential 25% gain over the next year.
- Summit Therapeutics Performance: Summit Therapeutics' stock has risen 2.4% since the war began, with a long crowding composite of just 18.1%, and analysts are generally bullish, as 13 out of 18 covering analysts rate it a buy or strong buy.
Summit Presents Updated Ivonescimab Data at ELCC 2026
- Clinical Data Update: Summit Therapeutics will present updated data on ivonescimab at the 2026 European Lung Cancer Congress, covering intracranial anti-tumor activity from the global HARMONi Phase III study, which is expected to attract industry attention and enhance the company's reputation in cancer immunotherapy.
- Improved Intracranial Survival: In the HARMONi study, patients receiving ivonescimab plus chemotherapy showed an intracranial progression-free survival (PFS) of 10.1 months compared to 6.5 months for chemotherapy alone, indicating the potential advantage of this therapy in EGFR-mutated non-small cell lung cancer (NSCLC) patients.
- Quality of Life Assessment: The second poster will showcase health-related quality of life data comparing ivonescimab with placebo plus chemotherapy, emphasizing the drug's potential to improve patient quality of life, which may enhance market recognition.
- Multiple Ongoing Trials: Ivonescimab is currently involved in over 15 Phase III clinical trials globally, covering various cancer types, indicating the company's extensive positioning in cancer treatment and future growth potential.
Jefferies Downgrades Summit Therapeutics with Target Price Cut
- Rating Downgrade: Jefferies downgraded Summit Therapeutics from Buy to Hold, reflecting a cautious market outlook on the company's future performance amid uncertainties.
- Target Price Revision: The target price was significantly cut from $42 to $15, indicating a reassessment of the company's growth potential, which may impact investor confidence and lead to stock price volatility.
- Clinical Trial Progress: Summit completed screening for the squamous cohort in Q1 2026, with enrollment for the non-squamous cohort expected to finish in the second half of the year, potentially supporting future treatment options for the company.
- Financial Performance: The company reported an adjusted EPS of -$0.14 for Q4, exceeding the market consensus of -$0.01, demonstrating operational resilience despite a challenging overall market environment.
Summit Therapeutics Faces FDA Review Risk for Ivonescimab
- Regulatory Application Progress: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, survival data from Western countries has not shown statistical significance, potentially jeopardizing its marketing authorization.
- Market Valuation Changes: Currently, Summit's market cap stands at $12 billion, approximately 48% higher than Axsome and 17% higher than Madrigal, but if the FDA declines ivonescimab, the stock could face a drop of over 20%.
- Competitor Dynamics: Axsome Therapeutics and Madrigal Pharmaceuticals reported revenue growth of 65.5% and 432% in 2025, respectively, indicating strong market potential that could see them surpass Summit in the near future.
- Investor Risk Assessment: While Summit has long-term potential in oncology, its short-term outlook is uncertain, prompting investors to carefully evaluate risks, especially in light of possible negative clinical trial outcomes.
Aehr Test Systems and MongoDB Show Active Options Trading
- Aehr Options Volume: Aehr Test Systems has seen an options trading volume of 23,837 contracts today, equating to approximately 2.4 million shares, which represents 69.3% of its average daily trading volume of 3.4 million shares over the past month.
- High Contract Analysis: Notably, the $90 strike call option expiring on April 17, 2026, has traded 1,933 contracts today, representing about 193,300 underlying shares, indicating market expectations for future price increases.
- MongoDB Options Activity: MongoDB Inc recorded an options trading volume of 10,127 contracts, representing approximately 1.0 million shares or 65.6% of its average daily trading volume of 1.5 million shares over the past month, highlighting investor interest in its future performance.
- Put Option Trading: The $230 strike put option expiring on April 17, 2026, has seen 714 contracts traded today, representing about 71,400 underlying shares, reflecting market concerns regarding potential downside risks for MongoDB.
Stifel Begins Coverage of Summit Therapeutics Inc with a Buy Rating and Sets Price Target at $45
Company Overview: Summit Therapeutics is focused on developing innovative therapies, particularly in the field of rare diseases and infectious diseases.
Investment Rating: The company has received a "Buy" rating from analysts, indicating positive expectations for its stock performance.
Price Target: Analysts have set a price target of $45 for Summit Therapeutics, suggesting significant potential for growth.
Market Position: The company is positioned to capitalize on its therapeutic developments, which may enhance its market presence and investor interest.
Citi Identifies Stocks with Upside Amid U.S.-Iran Conflict
- Market Turmoil Impact: The ongoing U.S.-Iran conflict has caused concern among investors, leading to a nearly 8% drop in the S&P 500 in March, marking its worst monthly performance since 2022.
- Citi Analyst Strategy: Citi analyst Richard Schlatter sought stocks that could sidestep recent volatility by overlaying crowding composites tracked by Citi, identifying stocks with positive catalysts that are not relatively crowded, aiming for a favorable reaction to fundamental tailwinds.
- Delta Air Lines Outlook: Delta Air Lines' stock has only dropped 3.8% this month, despite a nearly 9% decline in 2026, with Wall Street expecting a rebound; the average analyst price target from LSEG suggests a potential 25% gain over the next year.
- Summit Therapeutics Performance: Summit Therapeutics' stock has risen 2.4% since the war began, with a long crowding composite of just 18.1%, and analysts are generally bullish, as 13 out of 18 covering analysts rate it a buy or strong buy.
Summit Presents Updated Ivonescimab Data at ELCC 2026
- Clinical Data Update: Summit Therapeutics will present updated data on ivonescimab at the 2026 European Lung Cancer Congress, covering intracranial anti-tumor activity from the global HARMONi Phase III study, which is expected to attract industry attention and enhance the company's reputation in cancer immunotherapy.
- Improved Intracranial Survival: In the HARMONi study, patients receiving ivonescimab plus chemotherapy showed an intracranial progression-free survival (PFS) of 10.1 months compared to 6.5 months for chemotherapy alone, indicating the potential advantage of this therapy in EGFR-mutated non-small cell lung cancer (NSCLC) patients.
- Quality of Life Assessment: The second poster will showcase health-related quality of life data comparing ivonescimab with placebo plus chemotherapy, emphasizing the drug's potential to improve patient quality of life, which may enhance market recognition.
- Multiple Ongoing Trials: Ivonescimab is currently involved in over 15 Phase III clinical trials globally, covering various cancer types, indicating the company's extensive positioning in cancer treatment and future growth potential.
Jefferies Downgrades Summit Therapeutics with Target Price Cut
- Rating Downgrade: Jefferies downgraded Summit Therapeutics from Buy to Hold, reflecting a cautious market outlook on the company's future performance amid uncertainties.
- Target Price Revision: The target price was significantly cut from $42 to $15, indicating a reassessment of the company's growth potential, which may impact investor confidence and lead to stock price volatility.
- Clinical Trial Progress: Summit completed screening for the squamous cohort in Q1 2026, with enrollment for the non-squamous cohort expected to finish in the second half of the year, potentially supporting future treatment options for the company.
- Financial Performance: The company reported an adjusted EPS of -$0.14 for Q4, exceeding the market consensus of -$0.01, demonstrating operational resilience despite a challenging overall market environment.
Summit Therapeutics Faces FDA Review Risk for Ivonescimab
- Regulatory Application Progress: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, survival data from Western countries has not shown statistical significance, potentially jeopardizing its marketing authorization.
- Market Valuation Changes: Currently, Summit's market cap stands at $12 billion, approximately 48% higher than Axsome and 17% higher than Madrigal, but if the FDA declines ivonescimab, the stock could face a drop of over 20%.
- Competitor Dynamics: Axsome Therapeutics and Madrigal Pharmaceuticals reported revenue growth of 65.5% and 432% in 2025, respectively, indicating strong market potential that could see them surpass Summit in the near future.
- Investor Risk Assessment: While Summit has long-term potential in oncology, its short-term outlook is uncertain, prompting investors to carefully evaluate risks, especially in light of possible negative clinical trial outcomes.
